Protective Effect of Mesenchymal Stem Cells Against the Development of Intracranial Aneurysm Rupture in Mice

Overview

Journal Neurosurgery

Specialty Neurosurgery

Date 2017 Apr 22

PMID 28431181

Citations 16

Authors

Atsushi Kuwabara

Jia Liu

Yoshinobu Kamio

Airan Liu

Michael T Lawton

Jae-Woo Lee

Tomoki Hashimoto

Affiliations

Soon will be listed here.

Abstract

Background: Mesenchymal stem cells (MSCs) are multipotent stem or stromal cells found in multiple tissues. Intravenous MSC injections have been used to treat various diseases with an inflammatory component in animals and humans. Inflammation is emerging as a key component of pathophysiology of intracranial aneurysms. Modulation of inflammation by MSCs may affect sustained inflammatory processes that lead to aneurysmal rupture.

Objective: To assess the effect of MSCs on the development of aneurysm rupture using a mouse model.

Methods: Intracranial aneurysms were induced with a combination of a single elastase injection into the cerebrospinal fluid and deoxycorticosterone acetate salt-induced hypertension in mice. We administered allogeneic bone marrow-derived MSCs or vehicle, 6 and 9 d after aneurysm induction.

Results: MSC administration significantly reduced rupture rate (vehicle control vs MSCs, 90% vs 36%; P < .05). In cell culture experiments with an MSC and mast cell coculture, MSCs stabilized mast cells through cyclooxygenase-2 (COX-2)-dependent production of prostaglandin E2, thereby reducing the release of proinflammatory cytokines from mast cells. Pretreatment of MSCs with COX-2 inhibitor, NS-398, abolished the protective effect of MSCs against the development of aneurysm rupture.

Conclusion: Intravenous administration of MSCs after aneurysm formation prevented aneurysmal rupture in mice. The protective effect of MSCs against the development of aneurysm rupture appears to be mediated in part by the stabilization of mast cells by MSCs.

Citing Articles

Role and mechanisms of mast cells in brain disorders.

Huang X, Lan Z, Hu Z Front Immunol. 2024; 15:1445867.

PMID: 39253085 PMC: 11381262. DOI: 10.3389/fimmu.2024.1445867.

Therapeutic potential of stem cells in subarachnoid hemorrhage.

Kanamaru H, Suzuki H Neural Regen Res. 2024; 20(4):936-945.

PMID: 38989928 PMC: 11438332. DOI: 10.4103/NRR.NRR-D-24-00124.

Exosomes in Vascular/Neurological Disorders and the Road Ahead.

Alzahrani F, Riza Y, Eid T, Almotairi R, Scherschinski L, Contreras J Cells. 2024; 13(8.

PMID: 38667285 PMC: 11049650. DOI: 10.3390/cells13080670.

Aspirin treatment for unruptured intracranial aneurysms: Focusing on its anti-inflammatory role.

Feng Y, Zhang H, Dai S, Li X Heliyon. 2024; 10(7):e29119.

PMID: 38617958 PMC: 11015424. DOI: 10.1016/j.heliyon.2024.e29119.

Role of Circulating Exosomes in Cerebrovascular Diseases: A Comprehensive Review.

Lu Z, Tang H, Li S, Zhu S, Li S, Huang Q Curr Neuropharmacol. 2023; 21(7):1575-1593.

PMID: 36847232 PMC: 10472809. DOI: 10.2174/1570159X21666230214112408.

References

Meyer E, Buckley C, Thorpe S, Kelly D . Low oxygen tension is a more potent promoter of chondrogenic differentiation than dynamic compression. J Biomech. 2010; 43(13):2516-23. DOI: 10.1016/j.jbiomech.2010.05.020. View

Makino H, Hokamura K, Natsume T, Kimura T, Kamio Y, Magata Y . Successful serial imaging of the mouse cerebral arteries using conventional 3-T magnetic resonance imaging. J Cereb Blood Flow Metab. 2015; 35(9):1523-7. PMC: 4640342. DOI: 10.1038/jcbfm.2015.78. View

Wang J, Sjoberg S, Tia V, Secco B, Chen H, Yang M . Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice. Atherosclerosis. 2013; 229(2):304-9. PMC: 3724238. DOI: 10.1016/j.atherosclerosis.2013.05.025. View

Connolly Jr E, Rabinstein A, Carhuapoma J, Derdeyn C, Dion J, Higashida R . Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012; 43(6):1711-37. DOI: 10.1161/STR.0b013e3182587839. View

Nuki Y, Tsou T, Kurihara C, Kanematsu M, Kanematsu Y, Hashimoto T . Elastase-induced intracranial aneurysms in hypertensive mice. Hypertension. 2009; 54(6):1337-44. PMC: 2797444. DOI: 10.1161/HYPERTENSIONAHA.109.138297. View

Lee J, Fang X, Krasnodembskaya A, Howard J, Matthay M . Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011; 29(6):913-9. PMC: 3293251. DOI: 10.1002/stem.643. View

Monsel A, Zhu Y, Gennai S, Hao Q, Hu S, Rouby J . Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice. Am J Respir Crit Care Med. 2015; 192(3):324-36. PMC: 4584251. DOI: 10.1164/rccm.201410-1765OC. View

Pollock K, Dahlenburg H, Nelson H, Fink K, Cary W, Hendrix K . Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. Mol Ther. 2016; 24(5):965-77. PMC: 4881765. DOI: 10.1038/mt.2016.12. View

Brown J, Nemeth K, Kushnir-Sukhov N, Metcalfe D, Mezey E . Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. Clin Exp Allergy. 2011; 41(4):526-34. PMC: 3078050. DOI: 10.1111/j.1365-2222.2010.03685.x. View

10.

Jayaraman T, Berenstein V, Li X, Mayer J, Silane M, Shin Y . Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms. Neurosurgery. 2005; 57(3):558-64. DOI: 10.1227/01.neu.0000170439.89041.d6. View

11.

Choi S, Lee J, Wang K, Phi J, Song S, Song J . Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. Eur J Cancer. 2011; 48(1):129-37. DOI: 10.1016/j.ejca.2011.04.033. View

12.

Parekkadan B, Milwid J . Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010; 12:87-117. PMC: 3759519. DOI: 10.1146/annurev-bioeng-070909-105309. View

13.

Chen X, Armstrong M, Li G . Mesenchymal stem cells in immunoregulation. Immunol Cell Biol. 2006; 84(5):413-21. DOI: 10.1111/j.1440-1711.2006.01458.x. View

14.

Zhu Y, Feng X, Abbott J, Fang X, Hao Q, Monsel A . Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells. 2013; 32(1):116-25. PMC: 3947321. DOI: 10.1002/stem.1504. View

15.

Edjlali M, Gentric J, Regent-Rodriguez C, Trystram D, Hassen W, Lion S . Does aneurysmal wall enhancement on vessel wall MRI help to distinguish stable from unstable intracranial aneurysms?. Stroke. 2014; 45(12):3704-6. DOI: 10.1161/STROKEAHA.114.006626. View

16.

Lee R, Pulin A, Seo M, Kota D, Ylostalo J, Larson B . Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009; 5(1):54-63. PMC: 4154377. DOI: 10.1016/j.stem.2009.05.003. View

17.

Harting M, Jimenez F, Xue H, Fischer U, Baumgartner J, Dash P . Intravenous mesenchymal stem cell therapy for traumatic brain injury. J Neurosurg. 2009; 110(6):1189-97. PMC: 2889620. DOI: 10.3171/2008.9.JNS08158. View

18.

Prockop D . Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997; 276(5309):71-4. DOI: 10.1126/science.276.5309.71. View

19.

Prockop D, Brenner M, Fibbe W, Horwitz E, Le Blanc K, Phinney D . Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010; 12(5):576-8. DOI: 10.3109/14653249.2010.507330. View

20.

Uccelli A, Moretta L, Pistoia V . Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2009; 8(9):726-36. DOI: 10.1038/nri2395. View